Exicure

Exicure, Inc. is a clinical-stage biotechnology company based in Chicago, Illinois, focused on developing innovative therapeutics utilizing its proprietary spherical nucleic acid (SNA) technology. The company targets various medical fields, including neurology, immuno-oncology, inflammatory diseases, and genetic disorders. Its lead drug candidate, AST-008, is currently undergoing Phase 1b/2 clinical trials for advanced solid tumors. Additionally, Exicure is working on XCUR-FXN, an SNA-based therapeutic in preclinical trials for Friedreich’s ataxia, and XCUR17, which targets the messenger RNA for interleukin 17 receptor alpha. Exicure has entered agreements with Allergan Pharmaceuticals to explore SNA-based treatments for hair loss and with DERMELIX, LLC to develop treatments for Netherton syndrome. The company aims to address the challenges of nucleic acid therapeutics by improving cellular delivery and facilitating effective treatment for a range of diseases.